News

Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universitätsspital Zürich to predict patient response to biologic therapies, uncover resistance mechanisms, and identify novel drug targets.

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases.

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Darrin Crisitello as member of the BoD.

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings strong expertise in computational biology, immunology, and cancer research, with a track record of high-profile publications.